Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ia/Ib Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacodynamics of BBI-001 in Iron Deficient Volunteers and HH Patients

Next Previous
X
Search
Trial Profile

A Phase Ia/Ib Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacodynamics of BBI-001 in Iron Deficient Volunteers and HH Patients

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 08 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BBI-001 (Primary)
  • Indications Haemochromatosis
  • Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
  • Sponsors Bond Biosciences

    • Most Recent Events

    • 04 Jan 2024 According to Bond Biosciences media release, data from the study will be presented at at Biotech Showcase™ 2024. The Biotech Showcase is taking place in San Francisco in parallel with the J.P. Morgan 42nd Annual Healthcare Conference.
    • 01 Aug 2023 Status changed from recruiting to discontinued.
    • 20 Jul 2023 Results presented in a Bond Biosciences Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top